فصلنامه پژوهش های نوین در علوم پزشکی، بهداشت و سلامت شماره 2- دوره 2- صفحات210-193
Journal of new researches in Medical Sciences, Hygiene and Health
ISSN: 3060-625X

"Circulating Tumor DNA Variant Profiling for Early Cancer Detection: Advances, Challenges, and Clinical Translation"

Kimia Sadat Rasmi *[1]

1 . M.Sc. Student, Department of Biology, Faculty of Science, Central Tehran Branch, Islamic Azad University, Tehran, Iran.

Abstract

Circulating tumor DNA (ctDNA) variant profiling has emerged as a transformative approach in modern oncology, offering a minimally invasive and highly sensitive strategy for early cancer detection, disease monitoring, and precision therapeutic guidance. ctDNA consists of tumor-derived fragmented DNA circulating in the bloodstream, carrying genetic and epigenetic alterations that reflect the molecular landscape of malignant cells. Recent advancements in high-throughput sequencing, fragmentomics, methylation profiling, and computational modeling have significantly enhanced the analytical capability of ctDNA-based assays, enabling detection of cancers at earlier stages than conventional diagnostic modalities. The main objective of this review is to critically evaluate recent advances, methodological developments, clinical applications, and current limitations of ctDNA variant profiling in early cancer detection and translational oncology. This study is conducted as a narrative literature review based on recent peer-reviewed publications focusing on ctDNA technologies, clinical validation studies, and translational applications in oncology. The reviewed evidence indicates that ctDNA profiling has achieved substantial improvements in sensitivity and specificity through ultra-deep sequencing, tumor-informed assays, and integration of multi-omic signatures including DNA mutations, structural variants, and methylation patterns. Furthermore, large-scale studies demonstrate a strong correlation between ctDNA levels, tumor burden, and clinical outcomes, supporting its utility in minimal residual disease detection, treatment monitoring, and prognostic assessment. Findings also highlight that multi-cancer early detection platforms and longitudinal ctDNA monitoring can identify disease recurrence and therapeutic resistance earlier than traditional imaging methods. However, challenges such as low ctDNA abundance in early-stage cancers, clonal hematopoiesis interference, lack of standardization, and high implementation costs remain significant barriers to widespread clinical adoption. In conclusion, ctDNA variant profiling represents a rapidly evolving and highly promising tool in precision oncology, with strong potential to revolutionize early cancer detection and personalized treatment strategies. Continued technological innovation, clinical validation, and standardization efforts are essential to fully integrate ctDNA-based diagnostics into routine clinical practice.

Keywords: Circulating Tumor DNA, Liquid Biopsy, Early Cancer Detection, Precision Oncology, Next-Generation Sequencing

1. Introduction

Circulating tumor DNA (ctDNA) has emerged as one of the most transformative biomarkers in modern oncology, reshaping the conceptual and practical framework of cancer detection, monitoring, and precision medicine. ctDNA refers to short fragments of tumor-derived DNA released into the bloodstream through apoptosis, necrosis, and active secretion from cancer cells, and it represents a highly informative subset of total cell-free DNA (cfDNA) circulating in plasma. Unlike traditional tissue biopsies, which provide a static and spatially limited snapshot of tumor biology, ctDNA offers a dynamic, real-time molecular portrait of tumor evolution, heterogeneity, and treatment response. This has positioned ctDNA variant profiling as a cornerstone of liquid biopsy strategies, particularly in the context of early cancer detection where conventional imaging and histopathological methods often fail to identify disease at its most treatable stage (Chan et al., 2022; Kim & Park, 2023).

In recent years, advances in high-throughput sequencing technologies and ultra-sensitive molecular detection platforms have significantly expanded the clinical and analytical utility of ctDNA. Early studies demonstrated that ctDNA carries tumor-specific somatic mutations, copy number alterations, and structural variants that reflect the genomic landscape of the primary tumor and its metastases. More recently, research has extended beyond simple mutation detection to include fragmentomic characteristics, methylation signatures, and phased variant patterns, which collectively enhance detection sensitivity in low tumor burden settings. For instance, fragment length analysis of ctDNA has been shown to improve the discrimination between tumor-derived and normal cfDNA, offering a new dimension for molecular profiling in early-stage malignancies (Underhill, 2021). These technological developments have enabled the detection of ctDNA at variant allele frequencies below 0.1%, a threshold critical for identifying early-stage cancers and minimal residual disease (Kurtz et al., 2021; Chan et al., 2022).

The clinical relevance of ctDNA profiling is further underscored by large-scale cohort studies demonstrating its association with tumor burden and disease progression. In a comprehensive analysis of over 23,000 ctDNA samples, tumor fraction was found to strongly correlate with the detection of actionable genomic variants, highlighting the quantitative relationship between ctDNA abundance and clinical interpretability (Husain et al., 2022). Similarly, longitudinal profiling studies have revealed that ctDNA dynamics reflect clonal evolution under therapeutic pressure, enabling the identification of emerging resistance mutations and clinically actionable alterations in real time (Bosse et al., 2022). These findings collectively reinforce the role of ctDNA not only as a diagnostic biomarker but also as a powerful tool for disease monitoring and therapeutic decision-making across multiple cancer types (Chakravarty & Solit, 2021).

فصلنامه پژوهش های نوین در علوم پزشکی، بهداشت و سلامت شماره 2- دوره 2- صفحات210-193
Journal of new researches in Medical Sciences, Hygiene and Health
ISSN: 3060-625X



Figure 1. Conceptual Framework of ctDNA Variant Profiling in Early Cancer Detection and Clinical Translation

Figure 1 illustrates the comprehensive workflow of circulating tumor DNA (ctDNA) variant profiling, starting from tumor-derived DNA release into the bloodstream, followed by analytical processing using advanced genomic and epigenomic technologies, and culminating in diverse clinical applications including early cancer detection, minimal residual disease monitoring, therapeutic guidance, and prognosis assessment. The figure also highlights key translational outcomes and major biological and technical challenges that influence clinical implementation.

From a translational perspective, ctDNA-based assays are increasingly being integrated into clinical oncology workflows, particularly in precision medicine frameworks where genomic profiling guides treatment selection. Commercial and research-based platforms now allow for tumor-informed and tumor-naïve approaches to ctDNA analysis, each with distinct advantages in sensitivity, scalability, and clinical applicability. Tumor-informed assays, for example, leverage prior tumor tissue sequencing to design patient-specific panels for minimal residual disease detection, whereas tumor-naïve assays rely on broad gene panels applicable across heterogeneous patient populations. The clinical utility of these approaches has been demonstrated in multiple tumor types, including breast, prostate, and

neuroblastoma, where ctDNA profiling has successfully identified actionable mutations and monitored disease recurrence with high specificity (Kingston et al., 2021; Chi et al., 2023; Bosse et al., 2022).

Despite these advances, early cancer detection using ctDNA remains a complex and evolving challenge due to biological, technical, and clinical limitations. Low tumor shedding in early-stage disease, background noise from clonal hematopoiesis, and variability in cfDNA composition significantly complicate assay sensitivity and specificity. Nevertheless, ongoing research continues to address these limitations through methodological innovations such as methylation-based classification, structural variant enrichment, and multi-omic integration strategies. These developments suggest a growing convergence between genomics, computational biology, and clinical oncology, paving the way for ctDNA to become a foundational component of next-generation cancer screening programs (Papanicolau-Sengos & Aldape, 2022; Underhill, 2021; Chan et al., 2022).

2. Technological Foundations and Methodological Approaches

2.1 Next-Generation Sequencing and High-Sensitivity Mutation Detection

The foundation of circulating tumor DNA (ctDNA) variant profiling is built upon advances in next-generation sequencing (NGS) technologies, which have enabled the detection of ultra-low-frequency tumor-derived variants in a vast background of normal cell-free DNA. Traditional sequencing methods were limited by relatively high error rates and insufficient depth, making early-stage cancer detection largely unattainable. However, modern approaches such as ultra-deep sequencing combined with error-correction strategies—particularly unique molecular identifiers (UMIs)—have significantly improved analytical sensitivity and specificity. These methods allow the distinction between true somatic mutations and sequencing artifacts, enabling reliable detection of variant allele frequencies below 0.1%, which is critical for early cancer diagnosis and minimal residual disease assessment (Kurtz et al., 2021; Chan et al., 2022).

In clinical and translational oncology, targeted NGS panels focusing on recurrently mutated cancer genes have become the dominant strategy for ctDNA profiling due to their balance between sensitivity, cost-effectiveness, and interpretability. These panels are often designed based on known oncogenic drivers, allowing efficient detection of actionable mutations across multiple cancer types. Large-scale studies have demonstrated that such targeted sequencing approaches can identify clinically relevant genomic alterations in both advanced and early-stage malignancies, supporting their integration into precision oncology workflows (Chakravarty & Solit, 2021; Kim & Park, 2023). Furthermore, longitudinal sequencing studies highlight that repeated ctDNA sampling enhances detection power by

capturing temporal tumor evolution, which is particularly important in heterogeneous and dynamically evolving cancers (Bosse et al., 2022).

2.2 Fragmentomics, Structural Variants, and Epigenetic Profiling

Beyond traditional sequence-based mutation detection, recent methodological advancements have expanded ctDNA analysis into fragmentomics and structural variant profiling, significantly increasing diagnostic resolution. Fragmentomics refers to the study of cfDNA fragment size distributions and end-motifs, which differ between tumor-derived and non-tumor DNA due to distinct biological processes of DNA fragmentation. Tumor-derived cfDNA is often shorter and exhibits characteristic fragmentation patterns, which can be leveraged to enhance tumor signal detection even in cases where mutation burden is extremely low. This approach has been particularly valuable in early-stage cancer detection, where conventional mutation-based methods often fail due to insufficient ctDNA abundance (Underhill, 2021).

Structural variant (SV) detection has also emerged as a powerful complementary strategy in ctDNA profiling. Unlike single nucleotide variants, structural rearrangements such as deletions, duplications, and chromosomal translocations provide highly specific tumor signatures that can improve sensitivity in early disease settings. Recent studies in early-stage breast cancer have demonstrated that SV-based ctDNA detection can achieve ultrasensitive monitoring of disease progression and recurrence, offering a robust alternative to mutation-centric approaches (Elliott et al., 2025). In parallel, epigenetic profiling—particularly DNA methylation analysis—has introduced a tissue-of-origin dimension to ctDNA diagnostics, allowing not only cancer detection but also tumor localization. Aberrant methylation signatures are highly consistent across tumor types and can be detected even when mutational signals are absent, making them especially useful in early cancer screening applications (Papanicolau-Sengos & Aldape, 2022; Chan et al., 2022).

2.3 Personalized Assays, Tumor-Informed Strategies, and Computational Integration

A major advancement in ctDNA methodology is the development of personalized and tumor-informed assays, which significantly enhance sensitivity for minimal residual disease (MRD) detection and early recurrence monitoring. Tumor-informed approaches involve sequencing of primary tumor tissue to identify patient-specific somatic variants, which are then used to design highly customized ctDNA assays. This strategy dramatically increases detection sensitivity by focusing only on known tumor-specific mutations rather than broad genomic regions, thereby reducing background noise and

improving specificity. Clinical applications of these methods have demonstrated strong performance in tracking disease recurrence across multiple cancer types, particularly in high-risk solid tumors (Zhao et al., 2023; Kurtz et al., 2021).

In addition to personalized assay design, computational biology and machine learning have become integral to ctDNA data interpretation. Given the complexity and high dimensionality of ctDNA sequencing data, advanced bioinformatics pipelines are now employed to integrate mutational, fragmentomic, and epigenetic features into unified predictive models. These integrative frameworks enhance diagnostic accuracy and enable multi-cancer detection capabilities by identifying composite molecular signatures rather than relying on single biomarkers. Large-scale genomic profiling studies further support the importance of computational integration in improving variant interpretation, especially when distinguishing tumor-derived alterations from confounding biological processes such as clonal hematopoiesis (Chakravarty & Solit, 2021; Jaber et al., 2025).

3. Recent Advances in ctDNA Variant Profiling

3.1 Multi-Cancer Early Detection (MCED) and Integrated Genomic Signatures

One of the most significant recent advances in circulating tumor DNA (ctDNA) research is the development of multi-cancer early detection (MCED) assays, which aim to identify multiple cancer types from a single blood sample through integrated genomic and epigenomic signatures. Unlike earlier approaches that focused on single-gene mutation panels, MCED platforms combine somatic mutation detection, DNA methylation patterns, and fragmentomic features to construct a multi-dimensional molecular signature of cancer presence and tissue origin. This integrative strategy has significantly improved sensitivity in early-stage disease, where ctDNA abundance is extremely low and traditional mutation-only approaches often fail. By leveraging machine learning models trained on large genomic datasets, MCED assays are capable of distinguishing cancer-derived signals from non-malignant cfDNA with improved specificity across heterogeneous patient populations (Chan et al., 2022; Papanicolau-Sengos & Aldape, 2022). Clinical studies have demonstrated that these integrated approaches can detect cancers months to years before conventional imaging modalities, highlighting their potential as population-wide screening tools. Importantly, MCED systems have also shown promise in identifying tumor tissue of origin, which is critical for guiding diagnostic follow-up and clinical decision-making. The incorporation of methylation-based classifiers has been particularly impactful, as epigenetic alterations are more stable and tissue-specific compared to somatic mutations, enabling robust cancer detection even in cases with minimal tumor shedding (Papanicolau-Sengos & Aldape, 2022; Kim & Park, 2023).

3.2 Ultrasensitive Detection Strategies and Structural Variant Expansion

Recent advancements in ctDNA detection have focused heavily on increasing analytical sensitivity to capture ultra-low-frequency variants present in early-stage cancers. One major breakthrough has been the application of structural variant (SV)-based detection strategies, which exploit large-scale genomic rearrangements as highly specific tumor markers. Unlike point mutations, structural variants often represent clonal events that are preserved across tumor evolution, making them particularly useful for early detection and disease monitoring. In early-stage breast cancer, SV-based ctDNA profiling has demonstrated remarkable sensitivity improvements, allowing detection of tumor-derived DNA at levels previously considered below the analytical threshold of conventional sequencing approaches (Elliott et al., 2025). In parallel, technological innovations such as phased variant sequencing and error-suppression algorithms have further improved detection accuracy. Phased variant analysis allows the identification of co-occurring mutations on the same DNA fragment, thereby increasing confidence in true tumor-derived signals while reducing false positives. These advances are especially important in clinical settings where distinguishing true ctDNA from sequencing noise or clonal hematopoiesis remains a major challenge. Collectively, these innovations are pushing the boundaries of ctDNA detection toward clinically actionable sensitivity levels in early-stage malignancies (Kurtz et al., 2021; Chan et al., 2022).

3.3 Longitudinal Monitoring and Tumor Evolution Dynamics

Another major advancement in ctDNA research is its application in longitudinal monitoring of tumor evolution, enabling real-time assessment of disease progression and therapeutic response. Serial ctDNA sampling provides a dynamic view of tumor clonal architecture, revealing the emergence of resistance mutations and subclonal diversification under therapeutic pressure. This approach has been particularly valuable in high-risk cancers, where early detection of molecular relapse can guide timely intervention before radiological progression becomes evident. Studies in neuroblastoma and other aggressive malignancies have shown that ctDNA profiling can capture rapid genomic evolution, including the emergence of clinically actionable alterations during treatment (Bosse et al., 2022). Similarly, longitudinal ctDNA analysis has demonstrated strong prognostic value in advanced cancers, where baseline ctDNA levels and their dynamic changes correlate with survival outcomes and treatment efficacy. In renal cell carcinoma, for example, specific ctDNA alterations have been associated with disease prognosis and therapeutic response, reinforcing the clinical utility of serial

molecular monitoring (Kato et al., 2025). These findings underscore the role of ctDNA not only as a diagnostic tool but also as a real-time biomarker of tumor behavior and therapeutic resistance.

3.4 Clinical Validation and Expanding Real-World Applications

Recent years have also seen substantial progress in the clinical validation of ctDNA assays across large patient cohorts and real-world settings. Studies involving thousands of patients have demonstrated that ctDNA-based genomic profiling can reliably detect actionable mutations across a wide range of solid tumors, supporting its integration into routine clinical oncology workflows. Importantly, tumor fraction has been identified as a key determinant of ctDNA detectability, with higher tumor burden strongly correlating with increased likelihood of identifying clinically relevant variants (Husain et al., 2022). In addition to advanced disease settings, ctDNA is increasingly being evaluated in early-phase clinical trials as a pharmacodynamic and predictive biomarker. Its ability to reflect tumor burden in real time makes it particularly valuable for assessing early treatment response and guiding adaptive therapeutic strategies. Furthermore, personalized ctDNA assays are now being used in measurable residual disease (MRD) detection, offering highly sensitive tools for identifying microscopic disease after curative-intent therapy. These developments are accelerating the transition of ctDNA from a research-based biomarker to a clinically integrated diagnostic tool across oncology disciplines (Zhao et al., 2023; Tan et al., 2026).



Figure 2. Recent advances in ctDNA variant profiling for early cancer detection and clinical translation.

This schematic summarizes four major areas of progress in circulating tumor DNA (ctDNA) research. First, multi-cancer early detection (MCED) assays integrate somatic mutations, DNA methylation patterns, and fragmentomic features to improve cancer detection sensitivity and support tissue-of-origin prediction from a single blood sample. Second, ultrasensitive detection strategies have expanded beyond point mutations to include structural variants, phased variant sequencing, and advanced error-suppression methods, enabling detection of ultra-low-frequency tumor-derived signals in early-stage disease. Third, longitudinal monitoring through serial ctDNA sampling allows dynamic assessment of tumor evolution, therapeutic response, minimal residual disease, and emergence of resistance-associated alterations. Fourth, clinical validation and real-world application are advancing through large cohort studies and personalized assay development, supporting the integration of ctDNA profiling into precision oncology workflows.

4. Challenges and Limitations in ctDNA Variant Profiling

4.1 Biological Constraints and Analytical Sensitivity in Early-Stage Cancer Detection

Despite remarkable technological progress, one of the most fundamental challenges in circulating tumor DNA (ctDNA) variant profiling remains the inherently low abundance of ctDNA in early-stage cancers. In many patients with localized or pre-symptomatic disease, ctDNA may constitute less than 0.1% of total cell-free DNA, creating a severe signal-to-noise problem that limits detection sensitivity. This biological constraint is further complicated by intertumoral heterogeneity in DNA shedding rates, as some tumor types—such as high-grade or highly vascularized cancers—release significantly more ctDNA into circulation compared to indolent or early-lesion tumors. As a result, the absence of detectable ctDNA does not necessarily indicate the absence of disease, introducing a critical risk of false-negative findings in early cancer screening contexts (Chan et al., 2022; Kim & Park, 2023). In addition to low tumor fraction, biological confounders such as clonal hematopoiesis of indeterminate potential (CHIP) significantly impact assay specificity. CHIP-related mutations, which arise from age-associated expansion of hematopoietic stem cell clones, can be mistaken for tumor-derived variants, leading to false-positive results if not properly filtered. This issue is particularly problematic in older populations, where CHIP prevalence increases substantially and overlaps with the demographic most at risk for cancer. Furthermore, tumor heterogeneity adds another layer of complexity, as spatial and temporal variations in mutational profiles may result in incomplete representation of the tumor genome in circulating DNA. These biological limitations collectively underscore the need for cautious interpretation of ctDNA results, particularly in early detection settings where clinical consequences of false findings can be significant (Chakravarty & Solit, 2021; Husain et al., 2022).

4.2 Technical, Standardization, and Clinical Translation Barriers

Beyond biological constraints, ctDNA variant profiling faces substantial technical and methodological challenges that hinder its widespread clinical adoption. One of the primary issues is the lack of standardized protocols for sample collection, processing, sequencing, and bioinformatics analysis across laboratories. Pre-analytical variables such as blood collection tubes, plasma separation timing, and storage conditions can significantly affect cfDNA integrity and yield, introducing variability that compromises reproducibility across studies. Additionally, sequencing error rates—although greatly reduced by modern error-correction techniques—still present a non-negligible risk when detecting ultra-low-frequency variants, particularly in early-stage cancer detection where analytical thresholds are extremely stringent (Kurtz et al., 2021; Chan et al., 2022). Another major barrier is the absence of

universally accepted clinical guidelines for ctDNA interpretation and reporting. While ctDNA testing is increasingly integrated into precision oncology workflows, variability in assay design—ranging from tumor-informed personalized panels to broad tumor-naïve approaches—creates inconsistencies in clinical decision-making. This lack of harmonization complicates regulatory approval and limits the comparability of results across institutions. Furthermore, the cost and infrastructure requirements associated with high-depth sequencing and advanced computational analysis restrict accessibility, particularly in low-resource healthcare systems. Even as clinical utility continues to expand, these challenges highlight a significant gap between technological capability and routine clinical implementation, emphasizing the need for international standardization frameworks and validated analytical guidelines (Baden et al., 2026; Kim & Park, 2023).

5. Clinical Translation and Applications of ctDNA Variant Profiling

The clinical translation of circulating tumor DNA (ctDNA) variant profiling has progressed rapidly from experimental biomarker research to a clinically actionable tool in precision oncology. One of the most established applications is in advanced cancer management, where ctDNA is used for genomic profiling to guide targeted therapy selection. Unlike traditional tissue biopsies, which may be limited by sampling bias and tumor accessibility, ctDNA provides a minimally invasive and repeatable method for capturing the real-time mutational landscape of tumors. Clinical studies have demonstrated that ctDNA-based assays can reliably identify actionable mutations across a broad spectrum of solid tumors, supporting treatment stratification and therapeutic decision-making in routine oncology practice (Kim & Park, 2023; Kingston et al., 2021). This is particularly valuable in metastatic disease, where tumor heterogeneity and clonal evolution can significantly alter treatment response over time. Another major clinical application of ctDNA is in minimal residual disease (MRD) detection following curative-intent therapy such as surgery, chemotherapy, or radiotherapy. Tumor-informed ctDNA assays, which are designed based on patient-specific somatic mutations identified in tumor tissue, have shown high sensitivity for detecting microscopic residual disease that is undetectable by imaging. The presence of ctDNA after treatment has been strongly associated with disease recurrence and poor prognosis across multiple cancer types, making it a powerful prognostic biomarker for post-treatment monitoring. Serial ctDNA analysis further enhances clinical utility by enabling dynamic tracking of disease burden and early detection of relapse before clinical or radiological evidence emerges (Zhao et al., 2023; Kurtz et al., 2021).



Figure 3. Clinical translation and applications of ctDNA variant profiling

Figure 3. Clinical translation and applications of ctDNA variant profiling. Diagram summarizing the key clinical uses of circulating tumor DNA (ctDNA) variant profiling across the cancer care continuum: (1) genomic profiling to identify actionable alterations and guide targeted therapy selection in advanced/metastatic disease; (2) minimal residual disease (MRD) detection and post-treatment surveillance to predict recurrence before radiologic evidence; (3) real-time assessment of treatment response and monitoring of emerging resistance mechanisms to support therapy adaptation; and (4) population-level early cancer detection using multi-cancer early detection (MCED) assays integrating genomic and epigenomic ctDNA signals.

In addition to MRD assessment, ctDNA is increasingly being evaluated in early-phase clinical trials as a pharmacodynamic and predictive biomarker. Its rapid kinetics allow real-time assessment of treatment response, often preceding changes observed in imaging modalities. This has important implications for adaptive trial designs, where therapy can be modified based on early molecular response signals. Studies have also shown that baseline ctDNA levels and their dynamic changes correlate with clinical outcomes, including progression-free and overall survival, further reinforcing its role as a surrogate biomarker in drug development (Tan et al., 2026; Husain et al., 2022). In parallel,

real-world clinical studies are expanding the use of ctDNA in monitoring therapeutic resistance mechanisms, enabling timely switching of targeted therapies based on emerging genomic alterations. Despite these advances, the most ambitious application of ctDNA lies in population-level early cancer screening. Multi-cancer early detection (MCED) assays aim to identify asymptomatic cancers through integrated genomic and epigenomic signatures derived from ctDNA. While still under clinical validation, early results suggest that ctDNA-based screening could enable detection of cancers at significantly earlier stages than conventional diagnostic pathways, potentially improving survival outcomes. However, challenges such as false-positive rates, cancer type variability, and the absence of standardized follow-up protocols remain significant barriers to widespread implementation. Nevertheless, ongoing clinical trials and regulatory efforts suggest that ctDNA-based screening may become a foundational component of future preventive oncology strategies (Chan et al., 2022; Papanicolau-Sengos & Aldape, 2022; Kim & Park, 2023).

6. Findings and Conclusion: Integrated Synthesis and Future Perspectives

6.1 Integrated Findings from Current Evidence

Accumulated evidence from recent years demonstrates that circulating tumor DNA (ctDNA) variant profiling has fundamentally transformed the landscape of cancer diagnostics, moving oncology toward a minimally invasive, real-time, and highly personalized molecular framework. Across multiple tumor types, ctDNA has shown consistent utility in early detection, treatment monitoring, and minimal residual disease (MRD) assessment. However, its clinical maturity varies significantly depending on cancer stage, tumor type, and assay methodology. High-sensitivity sequencing, structural variant detection, and epigenetic integration have collectively expanded the detection capacity of ctDNA-based systems, particularly in low tumor burden settings where conventional imaging fails (Chan et al., 2022; Kurtz et al., 2021). Despite these advances, the clinical translation of ctDNA remains uneven due to biological and analytical constraints. Tumor shedding variability, clonal hematopoiesis interference, and lack of standardized pipelines continue to limit universal implementation. Nevertheless, longitudinal and large-scale studies confirm that ctDNA is strongly correlated with tumor burden, therapeutic response, and disease progression, reinforcing its role as both a diagnostic and prognostic biomarker (Husain et al., 2022; Bosse et al., 2022). The following tables synthesize the key dimensions of current evidence.

Table 1. Major Technological Advances in ctDNA Variant Profiling

Technology	Core Function	Clinical Impact	Key Reference
Ultra-deep NGS	High-resolution mutation detection	Early-stage cancer detection	Kurtz et al., 2021
Unique Molecular Identifiers (UMIs)	Error correction	Reduced sequencing noise	Chan et al., 2022
Fragmentomics	cfDNA size pattern analysis	Improved tumor signal detection	Underhill, 2021
Structural Variant Profiling	Detection of genomic rearrangements	High specificity in early cancer	Elliott et al., 2025
DNA Methylation Profiling	Epigenetic signature detection	Tissue-of-origin identification	Papanicolau-Sengos & Aldape, 2022
Tumor-informed Assays	Patient-specific mutation tracking	High MRD sensitivity	Zhao et al., 2023
Machine Learning Integration	Multi-omic data modeling	Improved diagnostic accuracy	Chan et al., 2022

Table 1 highlights the technological evolution of ctDNA profiling, demonstrating a shift from single-mutation detection toward integrated multi-omic platforms. The combination of genomic, epigenomic, and computational methods has significantly enhanced early detection capabilities. Studies consistently show that hybrid approaches outperform single-modality assays, especially in low tumor fraction conditions where sensitivity is critical for clinical utility (Chan et al., 2022; Underhill, 2021).

Table 2. Key Clinical Applications of ctDNA in Oncology

Application	Clinical Purpose	Cancer Stage	Key Evidence
Early Detection	Identify asymptomatic cancer	Preclinical/early stage	Chan et al., 2022
MRD Detection	Detect residual microscopic disease	Post-treatment	Kurtz et al., 2021

Therapy Selection	Identify actionable mutations	Advanced cancer	Kim & Park, 2023
Treatment Monitoring	Assess response dynamics	All stages	Bosse et al., 2022
Prognostic Assessment	Predict survival outcomes	Advanced cancer	Kato et al., 2025
Resistance Tracking	Detect emerging mutations	Metastatic disease	Kingston et al., 2021
Clinical Trials Biomarker	Evaluate drug efficacy	Experimental phase	Tan et al., 2026

Table 2 demonstrates that ctDNA has become a multi-functional biomarker spanning the entire cancer care continuum. Its strongest clinical utility is currently observed in advanced disease and MRD monitoring, while early detection remains an emerging but rapidly developing application. Evidence suggests that ctDNA-guided decision-making improves therapeutic precision and enables earlier intervention in cases of molecular relapse (Zhao et al., 2023; Kim & Park, 2023).

Table 3. Challenges and Future Research Directions in ctDNA Profiling

Challenge	Description	Impact	Proposed Solution
Low ctDNA abundance	Minimal tumor DNA in early stages	Reduced sensitivity	Signal amplification methods
Clonal hematopoiesis	False-positive mutation signals	Reduced specificity	Improved bioinformatic filtering
Tumor heterogeneity	Spatial/temporal genomic variation	Incomplete profiling	Multi-region sampling models
Lack of standardization	Variable lab protocols	Poor reproducibility	Global analytical guidelines

High cost	Expensive sequencing platforms	Limited accessibility	Cost-reduction technologies
Data complexity	Multi-omic integration difficulty	Analytical burden	AI-driven pipelines
Clinical validation gaps	Limited large-scale trials	Delayed adoption	Prospective cohort studies

Table 3 that while ctDNA technology is highly promising, its clinical adoption is constrained by significant biological and infrastructural challenges. Among these, low tumor fraction and lack of standardization remain the most critical barriers. Future advancements are expected to focus on integrating artificial intelligence, improving assay harmonization, and expanding large-scale validation studies to bridge the gap between research and clinical application (Baden et al., 2026; Chan et al., 2022).

6.2 Final Conclusion and Future Perspectives

In conclusion, circulating tumor DNA variant profiling represents one of the most significant advances in modern oncology, offering a paradigm shift from static tissue-based diagnostics to dynamic, non-invasive molecular monitoring. The integration of high-throughput sequencing, fragmentomics, methylation analysis, and computational modeling has significantly improved the sensitivity and clinical relevance of ctDNA-based assays. These innovations have enabled its application across multiple domains including early detection, MRD monitoring, treatment selection, and resistance surveillance. However, despite substantial progress, ctDNA has not yet reached full clinical maturity in population-wide cancer screening. Biological limitations such as low tumor shedding and technical challenges such as lack of standardization continue to restrict universal implementation. Nevertheless, ongoing large-scale validation studies and technological refinements suggest that ctDNA will play a central role in next-generation precision oncology frameworks. Future research should prioritize multi-omic integration, AI-based interpretation systems, and harmonized global clinical guidelines to fully realize its diagnostic potential. Ultimately, ctDNA variant profiling is expected to evolve from a supportive biomarker into a foundational pillar of early cancer detection and personalized medicine. Its ability to provide real-time insights into tumor biology positions it as a key tool in reducing cancer mortality through earlier intervention and more precise therapeutic strategies.

References

1. Page, K., Martinson, L. J., Fernandez-Garcia, D., Hills, A., Gleason, K. L., Gray, M. C., ... & Shaw, J. A. (2021). Circulating tumor DNA profiling from breast cancer screening through to metastatic disease. JCO Precision Oncology, 5, 1768-1776.
2. Chan, H. T., Chin, Y. M., & Low, S. K. (2022). Circulating tumor DNA-based genomic profiling assays in adult solid tumors for precision oncology: recent advancements and future challenges. Cancers, 14(13), 3275.
3. Husain, H., Pavlick, D. C., Fendler, B. J., Madison, R. W., Decker, B., Gjoerup, O., ... & Tukachinsky, H. (2022). Tumor fraction correlates with detection of actionable variants across> 23,000 circulating tumor DNA samples. JCO Precision Oncology, 6, e2200261.
4. Chakravarty, D., & Solit, D. B. (2021). Clinical cancer genomic profiling. Nature Reviews Genetics, 22(8), 483-501.
5. Elliott, M. J., Howarth, K., Main, S., Fuentes Antrás, J., Echelard, P., Dou, A., ... & Cescon, D. W. (2025). Ultrasensitive detection and monitoring of circulating tumor DNA using structural variants in early-stage breast cancer. Clinical Cancer Research, 31(8), 1520-1532.
6. Bosse, K. R., Giudice, A. M., Lane, M. V., McIntyre, B., Schürch, P. M., Pascual-Pasto, G., ... & Mossé, Y. P. (2022). Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma. Cancer discovery, 12(12), 2800-2819.
7. Kurtz, D. M., Soo, J., Co Ting Keh, L., Alig, S., Chabon, J. J., Sworder, B. J., ... & Alizadeh, A. A. (2021). Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nature biotechnology, 39(12), 1537-1547.
8. Zhao, J., Reuther, J., Scozzaro, K., Hawley, M., Metzger, E., Emery, M., ... & Daber, R. (2023). Personalized cancer monitoring assay for the detection of ctDNA in patients with solid tumors. Molecular Diagnosis & Therapy, 27(6), 753.
9. Kim, H., & Park, K. U. (2023). Clinical circulating tumor DNA testing for precision oncology. Cancer Research and Treatment: Official Journal of Korean Cancer Association, 55(2), 351-366.
10. Kingston, B., Cutts, R. J., Bye, H., Beaney, M., Walsh-Crestani, G., Hrebien, S., ... & Turner, N. C. (2021). Genomic profile of advanced breast cancer in circulating tumour DNA. Nature communications, 12(1), 2423.
11. Underhill, H. R. (2021). Leveraging the fragment length of circulating tumour DNA to improve molecular profiling of solid tumour malignancies with next-generation sequencing: a pathway to advanced non-invasive diagnostics in precision oncology?. Molecular Diagnosis & Therapy, 25(4), 389-408.
12. Chi, K. N., Barnicle, A., Sibilla, C., Lai, Z., Corcoran, C., Barrett, J. C., ... & Harrington, E. A. (2023). Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound. Clinical Cancer Research, 29(1), 81-91.

13. Papanicolau-Sengos, A., & Aldape, K. (2022). DNA methylation profiling: an emerging paradigm for cancer diagnosis. Annual Review of Pathology: Mechanisms of Disease, 17, 295-321.
14. Elliott, M. J., Howarth, K., Main, S., Fuentes Antrás, J., Echelard, P., Dou, A., ... & Cescon, D. W. (2025). Ultrasensitive detection and monitoring of circulating tumor DNA using structural variants in early-stage breast cancer. Clinical Cancer Research, 31(8), 1520-1532.
15. Jaber, D., Zhang, J., & Godley, L. A. (2025). Detecting likely germline variants during tumor-based molecular profiling. The Journal of Clinical Investigation, 135(15).
16. Kato, T., Shiota, M., Nishimoto, K., Matsubara, N., Osawa, T., Abe, T., ... & Nonomura, N. (2025). Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project: Genetics and Genomics. British journal of cancer, 133(1), 111-120.
17. Baden, J., Lin, C. H. J., Anfora, A. T., Beer, J., Bisselou, K., Bungo, J., ... & Leiman, L. C. (2026). Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation. JCO Precision Oncology, 10, e2500267.
18. Tan, H. N., Elliott, M. J., Silverman, I. M., Siu, L. L., & Yap, T. A. (2026). Circulating tumor DNA as a biomarker in early phase clinical trials. Cancer cell, 44(2), 240-247.
19. Gunaratne, R., Zhou, C., Rajaram, S., Tai, J. W., Tanaka, K., Tiwari, C., ... & Zhang, T. Y. (2026). Personalized Circulating Tumor DNA (ctDNA) Profiling Enables Superior and Universal Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML). medRxiv, 2026-01.